Loading
Loading
Research Overview
Dual glucagon and GLP-1 receptor agonist; the glucagon component drives increased hepatic fatty acid oxidation and thermogenesis while GLP-1 activity contributes to appetite suppression and insulin sensitisation.
Survodutide is a synthetic dual agonist peptide that engages both GLP-1 and glucagon receptors. Preclinical studies have investigated its metabolic effects in animal models, with particular attention to liver biology, where the glucagon receptor component may contribute to hepatic fat mobilisation while GLP-1 receptor engagement modulates inflammatory pathways.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, survodutide (bi 456906) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Survodutide (BI 456906) research is most relevant to protocols examining:
NASH and MASLD hepatic fat reduction research
Glucagon receptor biology and hepatic lipid metabolism studies
Dual GLP-1/glucagon mechanism research
Comparative studies with Pemvidutide and Retatrutide
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~7 days). Review data, confirm baseline recovery before any repeat protocol.
Dual glucagon and GLP-1 receptor agonist; the glucagon component drives increased hepatic fatty acid oxidation and thermogenesis while GLP-1 activity contributes to appetite suppression and insulin sensitisation.
| Parameter | Value |
|---|---|
| Dose range | Under investigation |
| Schedule | Once weekly |
| Route | Subcutaneous |
| Half-life | ~7 days |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.